Consider that we have these clusters that Leif Groop has suggested we can identify nowadays. And consider, now, to integrate those clusters with the information that we can gain from very advanced laboratory studies – the genetics, the omics, the microbiomics, and so on. So you might think that by that process it would be possible to identify even more granularity within the subgroups within the different clusters. And this granularity becomes very important in terms of selecting treatment – or the best treatment, in terms of better efficacy and reduced side effects, in terms of timing initiation of treatment and timing adding a new treatment or changing the treatment. So, I think precision medicine may help in the future. And if that is the case, you may also see how our lives as diabetologists must change. Because while what we’re doing today is sitting in front of the patient, discussing glucose parameters, cardiovascular risk and the risk of complications, maybe in the future we will be much more in an environment where the diabetologist looks more like a very technological expert, basing their decisions on genetics and omics information, on digital phenotyping, on sensor-based behaviour assessment and genomic-based pharmacotherapy. And, of course, there will be the use of artificial intelligence, in order to integrate all this information and to be able, as I initially said, to respond in a proper manner to the individual needs of each one of our patients.